{"success":true,"data":{"pressRelease":{"id":"37149","rtpr_id":"nGNE85ndbH","ticker":"NANOB","exchange":"Euronext Paris","all_tickers":["NANOB"],"title":"REG-Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer","author":"Globe Newswire","published_at":"2026-05-17T14:15:00.293Z","article_body":"Data presented by Johnson & Johnson at the 2026 European Society for\nRadiotherapy and Oncology (ESTRO) Annual Meeting\n\nPARIS and CAMBRIDGE, Mass., May 17, 2026 (GLOBE NEWSWIRE) --  NANOBIOTIX\n(https://www.globenewswire.com/Tracker?data=336AgiuVOy_-hKlDPYXmoWXopolUmOlItgRDYIoD--i41VEpAtApFjOA70IhLdAQ1aGDCOM-DeJ7lseZirThTQ==)\n(Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage\nbiotechnology company pioneering nanotherapeutic approaches to expand\ntreatment possibilities for patients with cancer and other major diseases,\ntoday announced the presentation of Part 1 data from the CONVERGE study, a\nJohnson & Johnson-sponsored randomized Phase 2 clinical trial evaluating\npotential first-in-class Nanoradioenhancer JNJ-1900 (NBTXR3) for patients with\nstage 3 inoperable non-small cell lung cancer (“NSCLC”), at the 2026\nEuropean Society for Radiotherapy and Oncology Annual Meeting (ESTRO 2026).\n\nPRESENTATION #116: Radiographic Response in Patients with Stage III\nUnresectable Non-Small Cell Lung Cancer Treated with an Intratumoral\nRadioenhancer (JNJ-90301900)\n\nJeffrey Bradley,(1) Benjamin T. Cooper,(2) Sushma Patel,(3) David\nDiBardino,(4) Michael Pritchett,(5) Kevin C. Ma,(4)   Isaac Laniado,(6)\nMelina E. Marmarelis,(7) Matthew Scarlotta,(8) Joshua K. Sabari,(9) Yi -Wen\nMa,(10) Tori Stromp,(10) Yina Kuang,(10) Balaji Laxmanan,(10 )Kiran\nDevisetty,(10) Steven Feigenberg(1)\n\nStudy Conclusions\n* Early results suggest that intratumoral/intranodal injection of JNJ-1900\n(NBTXR3) is feasible and can be performed safely in patients with stage III\nunresectable NSCLC\n* Initial efficacy responses observed in 7 patients following the full\ntreatment regimen of concurrent chemoradiotherapy, JNJ-1900 (NBTXR3), and\nconsolidation with durvalumab are promising:  * Overall response rate\n(“ORR”) = 85.7% (6/7 patients)\n* Complete response rate (“CRR”) = 57.1% (4/7 patients)  * With the\ncurrent standard of care, concurrent chemoradiation therapy (cCRT)\n± durvalumab, depth of response remains limited in Stage 3 Inoperable NSCLC\nwith very low rates of complete response (<5%) * \n  \n* Disease control rate (“DCR”) = 100.0% (7/7 patients)\n  \n* Absence of progressive disease and deepening response over time suggests\npotential for long-term durability\n(1)Radiation Oncology, University of Pennsylvania, Philadelphia, USA;\n(2)Radiation Oncology, NYU Langone Health, New York, USA; (3)Radiation\nOncology, FirstHealth of the Carolinas, Pinehurst, USA; (4)University of\nPennsylvania, Philadelphia, USA; (5)Interventional Pulmonology, FirstHealth of\nthe Carolinas, Pinehurst, USA; (6)Interventional Pulmonology, NYU Langone\nHealth, New York, USA; (7)Medical Oncology, University of Pennsylvania,\nPhiladelphia, USA; (8)Medical Oncology, FirstHealth of the Carolinas,\nPinehurst, USA; (9)Medical Oncology, NYU Langone Health, New York, USA;\n(10)Johnson & Johnson, New Brunswick, NJ, USA\n\n* Antonia SJ, et al. N Engl J Med. 2017.\n\nAbout JNJ-1900 (NBTXR3)\n\nJNJ-1900 (NBTXR3) is a novel, potentially first-in-class oncology product\ncomposed of functionalized hafnium oxide nanoparticles that is administered\nvia one-time intratumoral injection and activated by radiotherapy. Its\nproof-of-concept was achieved in soft tissue sarcomas through a successful\nrandomized Phase 2/3 study in 2018. The product candidate’s mechanism of\naction (MoA) is designed to induce significant tumor cell death in the\ninjected tumor when activated by radiotherapy, subsequently triggering\nadaptive immune response and long-term anti-cancer memory. Given the physical\nMoA, Nanobiotix believes that JNJ-1900 (NBTXR3) could be scalable across any\nsolid tumor that can be treated with radiotherapy and across any therapeutic\ncombination, particularly immune checkpoint inhibitors.\n\nRadiotherapy-activated JNJ-1900 (NBTXR3) is being evaluated across multiple\nsolid tumor indications as a single agent or combination therapy. The program\nis led by NANORAY-312—a global, randomized Phase 3 study in locally advanced\nhead and neck squamous cell cancers. In February 2020, the United States Food\nand Drug Administration granted regulatory Fast Track designation for the\ninvestigation of JNJ-1900 (NBTXR3) activated by radiation therapy, with or\nwithout cetuximab, for the treatment of patients with locally advanced HNSCC\nwho are not eligible for platinum-based chemotherapy—the same population\nbeing evaluated in the Phase 3 study.\n\nGiven the Company’s focus areas, and balanced against the scalable potential\nof NBTXR3, Nanobiotix has engaged in a collaboration strategy to expand\ndevelopment of the product candidate in parallel with its priority development\npathways. Pursuant to this strategy, in 2019 Nanobiotix entered into a broad,\ncomprehensive clinical research collaboration with The University of Texas MD\nAnderson Cancer Center to sponsor several Phase 1 and Phase 2 studies\nevaluating JNJ-1900 (NBTXR3) across tumor types and therapeutic combinations.\nIn 2023, Nanobiotix announced a license agreement for the global\nco-development and commercialization of JNJ-1900 (NBTXR3) with Janssen\nPharmaceutica NV, a Johnson & Johnson company.\n\nAbout NANOBIOTIX\n\nNanobiotix is a late-stage clinical biotechnology company pioneering\ndisruptive, physics-based therapeutic approaches to revolutionize treatment\noutcomes for millions of patients; supported by people committed to making a\ndifference for humanity. The Company’s philosophy is rooted in the concept\nof pushing past the boundaries of what is known to expand possibilities for\nhuman life.\n\nIncorporated in 2003, Nanobiotix is headquartered in Paris, France and is\nlisted on Euronext Paris since 2012 and on the Nasdaq Global Select Market in\nNew York City since December 2020. The Company has subsidiaries in Cambridge,\nMassachusetts (United States) amongst other locations.\n\nNanobiotix is the owner of more than 30 umbrella patents associated with three\n(3) nanotechnology platforms with applications in 1) oncology; 2)\nbioavailability and biodistribution; and 3) disorders of the central nervous\nsystem.\n\nFor more information about Nanobiotix, visit us at www.nanobiotix.com or\nfollow us on LinkedIn and Twitter.\n\nDisclaimer\n\nThis press release contains “forward-looking” statements within the\nmeaning of the “safe harbor” provisions of the Private Securities\nLitigation Reform Act of 1995, including, but not limited to, statements\nregarding the use of proceed therefrom, and the period of time through which\nthe Company’s anticipates its financial resources will be adequate to\nsupport operations. Words such as “expects”, “intends”, “can”,\n“could”, “may”, “might”, “plan”, “potential”, “should”\nand “will” or the negative of these and similar expressions are intended\nto identify forward-looking statements. These forward-looking statements which\nare based on the Company’ management’s current expectations and\nassumptions and on information currently available to management. These\nforward-looking statements involve known and unknown risks, uncertainties and\nother factors that could cause actual results to differ materially from those\nimplied by the forward-looking statements, including risks related to\nNanobiotix’s business and financial performance, which include the risk that\nassumptions underlying the Company’s cash runway projections are not\nrealized. Further information on the risk factors that may affect company\nbusiness and financial performance is included in Nanobiotix’s Annual Report\non Form 20-F filed with the SEC on March 31, 2026 under “Item 3.D. Risk\nFactors”, in Nanobiotix’s 2025 universal registration document filed with\nthe AMF on March 31, 2026 under “chapter 1.5 Risk Factors”, and subsequent\nfilings Nanobiotix makes with the SEC and AMF from time to time, which are\navailable on the SEC’s website at www.sec.gov and on the AMF's website at\nwww.amf.org, The forward-looking statements included in this press release\nspeak only as of the date of this press release, and except as required by\nlaw, Nanobiotix assumes no obligation to update these forward-looking\nstatements publicly.\n\n Nanobiotix                                                                                                                                                                                                                                                                                                              \n Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com  Investor Relations Department Joanne Choi VP, Investor Relations (US) +1 (713) 609-3150 joanne.choi@nanobiotix.com  Ricky Bhajun Director, Investor Relations (EU) +33 (0) 79 97 29 99 investors@nanobiotix.com    \n Media Relations                                                                                                                                                                                                                                                                                                         \n France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr                            Global – uncapped Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com                                                                                                                      \n\n \n\n \n\nAttachment\n*     2026-05-17 -- NBTX -- Part 1 Ph2 NBTXR3 In Stage 3 Lung Cancer -- FINAL\n(https://ml.globenewswire.com/Resource/Download/bc7eeb3c-06de-4bd2-a5dd-59041bd01ff0)","article_body_html":"","raw_payload":{"data":{"id":"nGNE85ndbH","title":"REG-Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer","author":"Globe Newswire","ticker":"NANOB","created":"2026-05-17T14:15:00.293Z","tickers":["NANOB"],"exchange":"Euronext Paris","article_body":"Data presented by Johnson & Johnson at the 2026 European Society for\nRadiotherapy and Oncology (ESTRO) Annual Meeting\n\nPARIS and CAMBRIDGE, Mass., May 17, 2026 (GLOBE NEWSWIRE) --  NANOBIOTIX\n(https://www.globenewswire.com/Tracker?data=336AgiuVOy_-hKlDPYXmoWXopolUmOlItgRDYIoD--i41VEpAtApFjOA70IhLdAQ1aGDCOM-DeJ7lseZirThTQ==)\n(Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage\nbiotechnology company pioneering nanotherapeutic approaches to expand\ntreatment possibilities for patients with cancer and other major diseases,\ntoday announced the presentation of Part 1 data from the CONVERGE study, a\nJohnson & Johnson-sponsored randomized Phase 2 clinical trial evaluating\npotential first-in-class Nanoradioenhancer JNJ-1900 (NBTXR3) for patients with\nstage 3 inoperable non-small cell lung cancer (“NSCLC”), at the 2026\nEuropean Society for Radiotherapy and Oncology Annual Meeting (ESTRO 2026).\n\nPRESENTATION #116: Radiographic Response in Patients with Stage III\nUnresectable Non-Small Cell Lung Cancer Treated with an Intratumoral\nRadioenhancer (JNJ-90301900)\n\nJeffrey Bradley,(1) Benjamin T. Cooper,(2) Sushma Patel,(3) David\nDiBardino,(4) Michael Pritchett,(5) Kevin C. Ma,(4)   Isaac Laniado,(6)\nMelina E. Marmarelis,(7) Matthew Scarlotta,(8) Joshua K. Sabari,(9) Yi -Wen\nMa,(10) Tori Stromp,(10) Yina Kuang,(10) Balaji Laxmanan,(10 )Kiran\nDevisetty,(10) Steven Feigenberg(1)\n\nStudy Conclusions\n* Early results suggest that intratumoral/intranodal injection of JNJ-1900\n(NBTXR3) is feasible and can be performed safely in patients with stage III\nunresectable NSCLC\n* Initial efficacy responses observed in 7 patients following the full\ntreatment regimen of concurrent chemoradiotherapy, JNJ-1900 (NBTXR3), and\nconsolidation with durvalumab are promising:  * Overall response rate\n(“ORR”) = 85.7% (6/7 patients)\n* Complete response rate (“CRR”) = 57.1% (4/7 patients)  * With the\ncurrent standard of care, concurrent chemoradiation therapy (cCRT)\n± durvalumab, depth of response remains limited in Stage 3 Inoperable NSCLC\nwith very low rates of complete response (<5%) * \n  \n* Disease control rate (“DCR”) = 100.0% (7/7 patients)\n  \n* Absence of progressive disease and deepening response over time suggests\npotential for long-term durability\n(1)Radiation Oncology, University of Pennsylvania, Philadelphia, USA;\n(2)Radiation Oncology, NYU Langone Health, New York, USA; (3)Radiation\nOncology, FirstHealth of the Carolinas, Pinehurst, USA; (4)University of\nPennsylvania, Philadelphia, USA; (5)Interventional Pulmonology, FirstHealth of\nthe Carolinas, Pinehurst, USA; (6)Interventional Pulmonology, NYU Langone\nHealth, New York, USA; (7)Medical Oncology, University of Pennsylvania,\nPhiladelphia, USA; (8)Medical Oncology, FirstHealth of the Carolinas,\nPinehurst, USA; (9)Medical Oncology, NYU Langone Health, New York, USA;\n(10)Johnson & Johnson, New Brunswick, NJ, USA\n\n* Antonia SJ, et al. N Engl J Med. 2017.\n\nAbout JNJ-1900 (NBTXR3)\n\nJNJ-1900 (NBTXR3) is a novel, potentially first-in-class oncology product\ncomposed of functionalized hafnium oxide nanoparticles that is administered\nvia one-time intratumoral injection and activated by radiotherapy. Its\nproof-of-concept was achieved in soft tissue sarcomas through a successful\nrandomized Phase 2/3 study in 2018. The product candidate’s mechanism of\naction (MoA) is designed to induce significant tumor cell death in the\ninjected tumor when activated by radiotherapy, subsequently triggering\nadaptive immune response and long-term anti-cancer memory. Given the physical\nMoA, Nanobiotix believes that JNJ-1900 (NBTXR3) could be scalable across any\nsolid tumor that can be treated with radiotherapy and across any therapeutic\ncombination, particularly immune checkpoint inhibitors.\n\nRadiotherapy-activated JNJ-1900 (NBTXR3) is being evaluated across multiple\nsolid tumor indications as a single agent or combination therapy. The program\nis led by NANORAY-312—a global, randomized Phase 3 study in locally advanced\nhead and neck squamous cell cancers. In February 2020, the United States Food\nand Drug Administration granted regulatory Fast Track designation for the\ninvestigation of JNJ-1900 (NBTXR3) activated by radiation therapy, with or\nwithout cetuximab, for the treatment of patients with locally advanced HNSCC\nwho are not eligible for platinum-based chemotherapy—the same population\nbeing evaluated in the Phase 3 study.\n\nGiven the Company’s focus areas, and balanced against the scalable potential\nof NBTXR3, Nanobiotix has engaged in a collaboration strategy to expand\ndevelopment of the product candidate in parallel with its priority development\npathways. Pursuant to this strategy, in 2019 Nanobiotix entered into a broad,\ncomprehensive clinical research collaboration with The University of Texas MD\nAnderson Cancer Center to sponsor several Phase 1 and Phase 2 studies\nevaluating JNJ-1900 (NBTXR3) across tumor types and therapeutic combinations.\nIn 2023, Nanobiotix announced a license agreement for the global\nco-development and commercialization of JNJ-1900 (NBTXR3) with Janssen\nPharmaceutica NV, a Johnson & Johnson company.\n\nAbout NANOBIOTIX\n\nNanobiotix is a late-stage clinical biotechnology company pioneering\ndisruptive, physics-based therapeutic approaches to revolutionize treatment\noutcomes for millions of patients; supported by people committed to making a\ndifference for humanity. The Company’s philosophy is rooted in the concept\nof pushing past the boundaries of what is known to expand possibilities for\nhuman life.\n\nIncorporated in 2003, Nanobiotix is headquartered in Paris, France and is\nlisted on Euronext Paris since 2012 and on the Nasdaq Global Select Market in\nNew York City since December 2020. The Company has subsidiaries in Cambridge,\nMassachusetts (United States) amongst other locations.\n\nNanobiotix is the owner of more than 30 umbrella patents associated with three\n(3) nanotechnology platforms with applications in 1) oncology; 2)\nbioavailability and biodistribution; and 3) disorders of the central nervous\nsystem.\n\nFor more information about Nanobiotix, visit us at www.nanobiotix.com or\nfollow us on LinkedIn and Twitter.\n\nDisclaimer\n\nThis press release contains “forward-looking” statements within the\nmeaning of the “safe harbor” provisions of the Private Securities\nLitigation Reform Act of 1995, including, but not limited to, statements\nregarding the use of proceed therefrom, and the period of time through which\nthe Company’s anticipates its financial resources will be adequate to\nsupport operations. Words such as “expects”, “intends”, “can”,\n“could”, “may”, “might”, “plan”, “potential”, “should”\nand “will” or the negative of these and similar expressions are intended\nto identify forward-looking statements. These forward-looking statements which\nare based on the Company’ management’s current expectations and\nassumptions and on information currently available to management. These\nforward-looking statements involve known and unknown risks, uncertainties and\nother factors that could cause actual results to differ materially from those\nimplied by the forward-looking statements, including risks related to\nNanobiotix’s business and financial performance, which include the risk that\nassumptions underlying the Company’s cash runway projections are not\nrealized. Further information on the risk factors that may affect company\nbusiness and financial performance is included in Nanobiotix’s Annual Report\non Form 20-F filed with the SEC on March 31, 2026 under “Item 3.D. Risk\nFactors”, in Nanobiotix’s 2025 universal registration document filed with\nthe AMF on March 31, 2026 under “chapter 1.5 Risk Factors”, and subsequent\nfilings Nanobiotix makes with the SEC and AMF from time to time, which are\navailable on the SEC’s website at www.sec.gov and on the AMF's website at\nwww.amf.org, The forward-looking statements included in this press release\nspeak only as of the date of this press release, and except as required by\nlaw, Nanobiotix assumes no obligation to update these forward-looking\nstatements publicly.\n\n Nanobiotix                                                                                                                                                                                                                                                                                                              \n Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com  Investor Relations Department Joanne Choi VP, Investor Relations (US) +1 (713) 609-3150 joanne.choi@nanobiotix.com  Ricky Bhajun Director, Investor Relations (EU) +33 (0) 79 97 29 99 investors@nanobiotix.com    \n Media Relations                                                                                                                                                                                                                                                                                                         \n France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr                            Global – uncapped Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com                                                                                                                      \n\n \n\n \n\nAttachment\n*     2026-05-17 -- NBTX -- Part 1 Ph2 NBTXR3 In Stage 3 Lung Cancer -- FINAL\n(https://ml.globenewswire.com/Resource/Download/bc7eeb3c-06de-4bd2-a5dd-59041bd01ff0)"},"type":"article","timestamp":"2026-05-17T14:15:00.36860244Z","server_sent_at_ms":1779027300368},"received_at":"2026-05-17T14:15:00.441Z","source_url":null},"analysis":{"id":"26592","press_release_id":"37149","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"Nanobiotix presented Part 1 data from the CONVERGE Phase 2 trial evaluating NBTXR3 in Stage 3 inoperable non-small cell lung cancer at ESTRO 2026.\n\nIn the initial cohort of 7 patients, the treatment achieved an 85.7% overall response rate and a 57.1% complete response rate, compared to less than 5% complete response with standard care.\n\nThe study also reported a 100% disease control rate, suggesting potential long-term durability and validating the nanoradioenhancer mechanism in a new solid tumor indication.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Strong Phase 2 data in NSCLC validates NBTXR3 mechanism, supporting broader oncology pipeline and J&J partnership."},"keyFigures":{"drugName":"JNJ-1900 (NBTXR3)","phaseOfTrial":"Phase 2","customDimensions":{"crr":"57.1%","dcr":"100.0%","orr":"85.7%","sor_crr":"<5%","patient_count":7}},"quotedText":"Early results suggest that intratumoral/intranodal injection of JNJ-1900 (NBTXR3) is feasible and can be performed safely in patients with stage III unresectable NSCLC","namedEntities":{"people":[{"name":"Jeffrey Bradley","role":"Lead Investigator"},{"name":"Benjamin T. Cooper","role":"Investigator"},{"name":"Brandon Owens","role":"VP, Communications"},{"name":"Joanne Choi","role":"VP, Investor Relations (US)"},{"name":"Ricky Bhajun","role":"Director, Investor Relations (EU)"}],"products":["JNJ-1900","NBTXR3","durvalumab"],"companies":[{"name":"Nanobiotix","ticker":"NBTX","relationship":"filer"},{"name":"Johnson & Johnson","ticker":"JNJ","relationship":"sponsor/partner"},{"name":"Janssen Pharmaceutica NV","relationship":"license partner"},{"name":"University of Texas MD Anderson Cancer Center","relationship":"research partner"}],"dollarAmounts":[]},"materialImpact":{"score":4,"reasoning":"Presentation of promising Phase 2 data for a key asset (NBTXR3) in a major indication (Stage 3 NSCLC). The results show an 85.7% ORR and 57.1% CRR, significantly outperforming the standard of care (<5% CRR). This validates the mechanism of action and supports the ongoing Phase 3 program in HNSCC, though it is not a binary regulatory approval."},"tickerRelevance":{"others":[{"ticker":"NBTX","relevance":"primary_listing"},{"ticker":"JNJ","relevance":"sponsor"}],"primary":"NANOB"},"globalImportance":45,"audienceRelevance":35,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"positive_clinical_data","sectorWeight":"high","householdBrandBoost":"low","marketCapAdjustment":"neutral","retailFavoriteBoost":"low"}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":4,"narrative":"Nanobiotix presented Part 1 data from the CONVERGE Phase 2 trial evaluating NBTXR3 in Stage 3 inoperable non-small cell lung cancer at ESTRO 2026.\n\nIn the initial cohort of 7 patients, the treatment achieved an 85.7% overall response rate and a 57.1% complete response rate, compared to less than 5% complete response with standard care.\n\nThe study also reported a 100% disease control rate, suggesting potential long-term durability and validating the nanoradioenhancer mechanism in a new solid tumor indication.","key_figures":{"drugName":"JNJ-1900 (NBTXR3)","phaseOfTrial":"Phase 2","customDimensions":{"crr":"57.1%","dcr":"100.0%","orr":"85.7%","sor_crr":"<5%","patient_count":7}},"named_entities":{"people":[{"name":"Jeffrey Bradley","role":"Lead Investigator"},{"name":"Benjamin T. Cooper","role":"Investigator"},{"name":"Brandon Owens","role":"VP, Communications"},{"name":"Joanne Choi","role":"VP, Investor Relations (US)"},{"name":"Ricky Bhajun","role":"Director, Investor Relations (EU)"}],"products":["JNJ-1900","NBTXR3","durvalumab"],"companies":[{"name":"Nanobiotix","ticker":"NBTX","relationship":"filer"},{"name":"Johnson & Johnson","ticker":"JNJ","relationship":"sponsor/partner"},{"name":"Janssen Pharmaceutica NV","relationship":"license partner"},{"name":"University of Texas MD Anderson Cancer Center","relationship":"research partner"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-17T14:15:22.102Z","global_importance":45,"audience_relevance":35,"importance_components":{"tickerTier":"mid-cap","eventGravity":"positive_clinical_data","sectorWeight":"high","householdBrandBoost":"low","marketCapAdjustment":"neutral","retailFavoriteBoost":"low"}},"durationMs":21588,"modelName":"george-droid-qwen-72b"}}